Colorectal Surgeon Dr. Julio Garcia-Aguilar, MD, PhD (seated) with nurse Kieran Kelleher BSN-RN. Dr. Garcia-Aguilar and the colorectal service at MSK are experts at the watch and wait approach to ...
Neoadjuvant treatment with a programmed cell death 1 (PD-1) inhibitor induces clinical complete response and leads to organ preservation in a high proportion of patients with early-stage, mismatch ...
New data indicate that nonoperative surveillance after removing a malignant colorectal polyp can achieve high rates of rectal ...
New cancer research pioneered by Memorial Sloan Kettering points to a strong alternative to chemotherapy, surgery and radiation for some forms of cancer. Nearly 80% of patients who suffered from a ...
Surgery and chemotherapy together improved survival in GIST patients with liver metastases, increasing median cancer-specific ...
New cancer research pioneered by Memorial Sloan Kettering points to a strong alternative to chemotherapy, surgery, and radiation for some forms of cancer. Nearly 80% of patients who suffered from a ...
A retrospective study of patients with distal rectal cancer at Memorial Sloan Kettering Cancer Center (MSK) has found a higher rate of local recurrence after intersphincteric resection with handsewn ...
Use of a neoadjuvant checkpoint inhibitor enabled a high proportion of patients with early-stage mismatch repair-deficient (dMMR) solid tumors to avoid surgery and achieve organ preservation in a ...
Dostarlimab treatment led to complete clinical responses in 82% of patients with dMMR tumors, avoiding surgery for most. Recurrence-free survival at two years was 92%, with a median follow-up of 20 ...
Morning Overview on MSN
Tumors disappeared with this new drug, minus the scary toxicity
For decades, cancer patients have been told that shrinking tumors meant accepting brutal side effects as the price of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback